ReviewFrontiers in cardiovascular medicine2017
Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease.
Review in Frontiers in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- A randomized clinical trial to evaluate the effects of icodextrin on left ventricular mass index in peritoneal dialysis.Scientific reports · 2022Trial
- Leptin promotes endothelial dysfunction in chronic kidney disease by modulating the MTA1-mediated WNT/β-catenin pathway.Molecular and cellular biochemistry · 2020Trial
- Artificial intelligence in nephrology: predicting CKD progression and personalizing treatment.International urology and nephrology · 2026Review
- Multimodal Detection of Subclinical Cardiovascular Disease in Chronic Kidney Disease.Cardiorenal medicine · 2026Review
- NT-proBNP as an Independent Predictor of Long-Term All-Cause Mortality in Heart Failure Across the Spectrum of Glomerular Filtration Rate.Journal of clinical medicine · 2025Article
- N-terminal pro-B-type natriuretic peptide, eGFR, and progression of kidney disease in chronic kidney disease patients without heart failure.Clinical kidney journal · 2024Article
- A Pilot Study of the Role of Selected Biomarkers of Kidney Injury in Dogs with Dilated Cardiomyopathy.Animals : an open access journal from MDPI · 2024Article
- Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Observational
- NT-proBNP as predictor of major cardiac events after renal transplantation in patients with preserved left ventricular ejection fraction.BMC nephrology · 2023Article
- Fibroblast growth factor 23 in children with or without heart failure: a prospective study.BMJ paediatrics open · 2023Article
- Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.International urology and nephrology · 2022Article
- Perioperative variation in serum FGF-23 level and its correlation with MACCE risk in unprotected left main coronary artery disease patients receiving coronary artery bypassing grafting.Frontiers in surgery · 2022Article
- Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction.ESC heart failure · 2020Article
- Mildly Elevated Cardiac Troponin below the 99th-Percentile Upper Reference Limit after Noncardiac Surgery.Korean circulation journal · 2020Article
- Early myocardial injury biomarkers in diabetic hyperlipidemic rats: Impact of 10-dehydrogingerdione and vitamin D3.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy.Frontiers in cardiovascular medicine · 2020Review
- Role of copeptin as a novel biomarker of bisphenol A toxic effects on cardiac tissues: biochemical, histological, immunohistological, and genotoxic study.Environmental science and pollution research international · 2019Article
- Effects of a Structured Physical Activity Program on Serum Adipokines and Markers of Inflammation and Volume Overload in Kidney Transplant Recipients.Annals of transplantation · 2019Article
- BNP as a Major Player in the Heart-Kidney Connection.International journal of molecular sciences · 2019Review
- Stromal Cell-derived Factor-1 and CXC Chemokine Receptor Type-4 are Associated with Cardiovascular Disease in Patients under Hemodialysis.International journal of preventive medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mortality among the patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains high because of the very high incidence of cardiovascular disease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early diagnosis and therapy for CVD is crucial in these patients. Therefore, it is necessary for the better management to identify and utilize cardiovascular (CV) biomarkers in profiling CVD risk and enabling stratification of early mortality. This review summarizes current evidence about renocardiovascular biomarkers: CV biomarkers in patients with CKD as well as with ESRD, emphasizing on the emerging biomarkers: B-type natriuretic peptide, cardiac troponins, copeptin, the biomarker of renal injury (neutrophil gelatinase-associated lipocalin), and the mineral and bone disorder hormone/marker (fibroblast growth factor-23). Furthermore, it discusses their potential roles especially in ESRD and in future diagnostic and therapeutic strategies for CVD in the context of managing cardiorenal syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.